City

Guangzhou (1)

Condition

HRR Gene Mutation (1)

Her-2 Negative Breast Cancer (1)

Overall Status

Recruiting (1)

Sign in for free

Phase

phase 2 (1)

Sponsor

Ying Lin (1)

Collaborator

Intervention

camrelizumab (1)

fluzoparib (1)

nab-paclitaxel (1)

Study Documents

Intervention Type

drug (1)

Funder Type

Other (1)

Study Type

Interventional (1)

hrr gene mutation

Showing 1 - 1 of 1

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

Her-2 Negative Breast Cancer, HRR Gene Mutation Trial in Guangzhou (Camrelizumab, Fluzoparib, Nab-paclitaxel)

Recruiting

Her-2 Negative Breast Cancer
HRR Gene Mutation

Camrelizumab
+2 more

Guangzhou, Guangdong, China

First Affiliated Hospital, Sun Yat-Sen University

Mar 7, 2023